India’s Rise as the “Pharmacy of the World” Fuels Global Health Equity
The promise of affordable healthcare for all is moving closer to reality, largely thanks to the burgeoning pharmaceutical industry in India. Beyond serving its own population of over 1.4 billion, India has become a critical supplier of medications – from essential generics to cutting-edge treatments – to countries worldwide. This role was particularly evident during the COVID-19 pandemic, where India emerged as a leading producer and exporter of vaccines, playing a vital role in the global fight against the virus. The nation’s pharmaceutical sector is not merely focused on production; it’s increasingly shaping the landscape of global health access and affordability.
Driven by a commitment to universal health coverage – the principle that everyone, regardless of income, should have access to quality healthcare – India’s pharmaceutical companies are offering low-cost drugs both domestically and internationally. This isn’t simply a matter of individual well-being; it’s a strategic investment in a stronger, more productive society, aligning with India’s vision of becoming a fully developed nation by 2047. The sector’s growth is fueled by government support, private sector innovation, and a growing demand for accessible healthcare solutions.
Recent initiatives, including the Union Budget 2026-27, demonstrate a strong commitment to bolstering India’s pharmaceutical capabilities. The budget introduces the Biopharma SHAKTI programme, a INR 10,000 crore (approximately $120 million USD as of March 3, 2026) initiative designed to establish India as a global hub for biologics and biosimilars. Alongside this, strategic customs duty exemptions on 17 critical drugs, with a particular focus on cancer treatments, and expanded coverage for seven additional rare diseases, aim to improve patient access to essential medications. These measures signal a proactive approach to strengthening both the industry and public health outcomes.
Robust Growth and Market Dynamics
India’s pharmaceutical sector has experienced consistent growth, reaching a market size of USD 50.41 billion in 2024 and growing at approximately 10% annually, according to data from Akhand Partners. As the world’s third-largest pharmaceutical market by volume and eleventh largest by value, India currently supplies approximately 20% of global generic medicine demand. This position is a testament to the country’s manufacturing capabilities and its commitment to providing affordable alternatives to branded drugs.
The sector’s resilience is evident in its recovery trajectory. Following disruptions caused by the pandemic, growth stabilized around 10% in recent years. This performance is driven by strong domestic demand, expanding export markets, and increasing penetration of chronic therapy segments. The industry is poised for continued growth, with projections estimating a 7-9% expansion in fiscal year 2026. This sustained growth is attracting significant investment and fostering innovation within the sector.
| Year | Market Size (USD Million) | Growth Rate (%) |
|---|---|---|
| 2021 | 44,197.24 | 13.1 |
| 2022 | 46,188.80 | 4.8 |
| 2023 | 47,217.00 | 10.2 |
| 2024 | 50,410.07 | 10.0 |
The Rise of Biopharmaceuticals and Medical Tourism
India is rapidly becoming a hotspot for biopharmaceutical development, fueled by government support and private sector investment. The Biopharma SHAKTI programme is a key component of this strategy, aiming to create a robust ecosystem for the research, development, and manufacturing of biologics and biosimilars. These complex therapies, often used to treat chronic and life-threatening diseases, represent a significant growth opportunity for the Indian pharmaceutical industry.
This growth is also driving a surge in medical tourism. The number of international patients seeking treatment in India has increased dramatically, rising from approximately 112,000 in 2009 to over 600,000 in 2024. Patients are drawn to India by the availability of affordable, high-quality medical care, including complex procedures and specialized treatments. The Union Budget for 2026-27 further supports this trend with plans to establish five new integrated medical hubs, offering comprehensive testing and recovery services through public-private partnerships.
Government Initiatives and Domestic Access
The Indian government has implemented several programs to improve access to affordable medicines for its citizens. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) operates nearly 18,000 outlets across the country, offering over 2,000 different medicines and 300 surgical items at discounts of up to 90%. This initiative provides crucial access to treatments for common conditions like heart disease, cancer, and diabetes. The Affordable Medicines and Reliable Implants for Treatment (AMRIT) scheme ensures that public hospitals have access to key drugs and devices at reduced prices.
the Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (PM-JAY) provides health insurance coverage to millions of low-income families, while programs like Ayushman Arogya Mandirs and the National Health Mission strengthen grassroots healthcare delivery. These combined efforts are significantly improving access to medicines and reducing the financial burden on families.
Challenges and Future Outlook
Despite its impressive growth, India’s pharmaceutical industry faces several challenges. Maintaining consistent quality control across a vast and diverse population remains a priority. Supply chain pressures, rising raw material costs, and the need to balance domestic and international demand also pose ongoing hurdles. The presence of counterfeit drugs remains a serious concern, requiring continued vigilance and stricter regulatory enforcement.
Looking ahead, the Indian pharmaceutical industry is well-positioned for continued success. Policies that promote local manufacturing, encourage research and development, and foster collaboration between the public and private sectors will be crucial. Reducing reliance on imported active pharmaceutical ingredients (APIs) and enhancing self-sufficiency are also key priorities. The industry’s ability to navigate these challenges will determine its long-term sustainability and its continued role as a global leader in affordable healthcare.
Key Takeaways
- India is a major global supplier of generic medicines, providing approximately 20% of the world’s demand.
- The Union Budget 2026-27 includes significant investments in the biopharmaceutical sector through the Biopharma SHAKTI programme.
- Government initiatives like the PMBJP and PM-JAY are improving access to affordable medicines for millions of Indians.
- Medical tourism is booming in India, driven by the availability of high-quality, affordable healthcare.
- Challenges remain in ensuring quality control, managing supply chains, and combating counterfeit drugs.
The next key development to watch will be the implementation of the Biopharma SHAKTI programme and the establishment of the new integrated medical hubs announced in the Union Budget 2026-27. These initiatives are expected to significantly impact the Indian pharmaceutical landscape in the coming years. We encourage readers to share their thoughts and experiences with India’s pharmaceutical industry in the comments below.